Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis
- PMID: 31308202
- DOI: 10.3899/jrheum.190268
Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis
Abstract
Objective: Inconsistent assessment and treatment may impair juvenile idiopathic arthritis (JIA) outcomes. We aimed to improve polyarticular JIA (rheumatoid factor-positive and -negative) outcomes by standardizing point-of-care disease activity monitoring and implementing clinical decision support (CDS) to reduce treatment variation.
Methods: We performed a quality improvement initiative in an outpatient pediatric rheumatology practice. The interventions, implemented from April to November 2016, included standardized disease activity measurement, disease activity target review, and phased introduction of polyarticular JIA CDS to guide medication selection, dosing, treatment duration, and tapering. Process measures included visit-level target attestation (goal: 50%) and CDS use (goal: 15%). Our goal was to reduce the polyarticular JIA clinical Juvenile Arthritis Disease Activity Score (cJADAS-10) by at least 10%. Included patients had at least 2 visits from April 2016 through July 2017, and were classified as having early (≤ 6 mos) or established disease (> 6 mos).
Results: Patients with polyarticular JIA (n = 97; 81% established disease) were observed for 10.3 months (interquartile range: 6.4-12.3). Target attestation and CDS use occurred in a mean of 77% and 45% of polyarticular JIA visits, respectively. The median cJADAS-10 decreased significantly in both early (16.5 to 2.7, p < 0.001) and established polyarticular JIA (2.1 to 1.0, p = 0.01). A high proportion of patients with early disease received biologic therapy (73.7%). In established disease, although prescription of nonbiologic and biologic disease-modifying antirheumatic drugs remained similar overall, adalimumab prescribing increased (12.8% to 23.1%, p = 0.008).
Conclusion: Implementation of structured disease activity monitoring and CDS in polyarticular JIA was associated with significant reductions in disease activity scores in both early and established disease.
Keywords: CLINICAL DECISION SUPPORT SYSTEMS; JUVENILE IDIOPATHIC ARTHRITIS; OUTCOMES ASSESSMENT.
Similar articles
-
Determinants of disease activity change over time in Enthesitis related arthritis: effect of structured outcome monitoring and clinical decision support.Pediatr Rheumatol Online J. 2020 Oct 15;18(1):79. doi: 10.1186/s12969-020-00472-3. Pediatr Rheumatol Online J. 2020. PMID: 33059694 Free PMC article.
-
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.Arthritis Rheumatol. 2021 Oct;73(10):1910-1920. doi: 10.1002/art.41892. Epub 2021 Aug 27. Arthritis Rheumatol. 2021. PMID: 34105303
-
Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.Pediatr Rheumatol Online J. 2017 Nov 7;15(1):78. doi: 10.1186/s12969-017-0206-9. Pediatr Rheumatol Online J. 2017. PMID: 29116003 Free PMC article. Review.
-
Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.Arthritis Rheumatol. 2021 Oct;73(10):1898-1909. doi: 10.1002/art.41888. Epub 2021 Sep 3. Arthritis Rheumatol. 2021. PMID: 34105312 Free PMC article.
-
An update on the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis.Expert Opin Drug Saf. 2025 Jun;24(6):627-642. doi: 10.1080/14740338.2025.2467179. Epub 2025 Feb 16. Expert Opin Drug Saf. 2025. PMID: 39946290 Review.
Cited by
-
Determinants of disease activity change over time in Enthesitis related arthritis: effect of structured outcome monitoring and clinical decision support.Pediatr Rheumatol Online J. 2020 Oct 15;18(1):79. doi: 10.1186/s12969-020-00472-3. Pediatr Rheumatol Online J. 2020. PMID: 33059694 Free PMC article.
-
[Artificial intelligence-supported treatment in rheumatology : Principles, current situation and perspectives].Z Rheumatol. 2021 Dec;80(10):914-927. doi: 10.1007/s00393-021-01096-y. Epub 2021 Oct 7. Z Rheumatol. 2021. PMID: 34618208 Free PMC article. Review. German.
-
Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the "comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS" (STARS) trial.Pediatr Rheumatol Online J. 2022 Sep 7;20(1):80. doi: 10.1186/s12969-022-00739-x. Pediatr Rheumatol Online J. 2022. PMID: 36071444 Free PMC article. Clinical Trial.
-
2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis.Arthritis Care Res (Hoboken). 2022 Apr;74(4):521-537. doi: 10.1002/acr.24853. Epub 2022 Mar 1. Arthritis Care Res (Hoboken). 2022. PMID: 35233986 Free PMC article.
-
Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?J Clin Med. 2022 Sep 26;11(19):5674. doi: 10.3390/jcm11195674. J Clin Med. 2022. PMID: 36233546 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous